Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Patients with Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).

Start Date30 Mar 2023

Sponsor / Collaborator

University of Pittsburgh

[+2]

NCT05868226 / RecruitingPhase 1

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Start Date22 Dec 2022

Sponsor / Collaborator

Quantumleap Healthcare Collaborative

NCT05524545 / RecruitingPhase 1

A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)

AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.

Start Date02 Nov 2022

Sponsor / Collaborator

ALX Oncology, Inc.

100 Clinical Results associated with Evorpacept

100 Translational Medicine associated with Evorpacept

100 Patents (Medical) associated with Evorpacept

Literatures (Medical) associated with Evorpacept

01 Jul 2024·CURRENT OPINION IN ONCOLOGY

State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies

Review

Author: Lee, Jaeyop ; Ku, Geoffrey

Purpose of review:

This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.

Recent findings:

The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.

Summary:

The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.

01 Jan 2024·TRANSFUSION MEDICINE AND HEMOTHERAPY

Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing

Article

Author: Kim, Tae Yeul ; Yoon, Eungjun ; Kim, Hyungsuk ; Cho, Duck

Introduction: Evorpacept is a CD47-blocking agent currently being developed for the treatment of various cancers. Interference by evorpacept in pretransfusion compatibility testing has been reported at limited plasma concentrations. Although various mitigation strategies have been proposed, none are practical. This in vitro study assessed evorpacept-induced interference at extended concentrations and investigated the capability of a novel mitigation agent, Evo-NR. Methods: Antibody screening tests were performed on evorpacept-spiked plasma with (anti-E and anti-Jk^a) or without alloantibodies at evorpacept concentrations up to 2,000 μg/mL using manual gel cards and automated analyzers. Evorpacept-coated red blood cells (RBCs) (rr [ce/ce], Fy[a+b−], S−s+) were tested by direct antiglobulin testing (DAT) and antigen typing using anti-Fy^b and anti-S reagents at indirect antiglobulin testing (IAT) phase. Evo-NR was used to resolve the interference in plasma and RBC samples. Flow cytometry was used to assess the mitigation effects. Results: Evorpacept-spiked plasma showed panreactive interference in antibody screening tests using manual gel cards (2+ to 3+) and automated analyzers (4+). A carryover effect was also observed in the automated analyzers. The use of a 3- to 6-fold molar excess of Evo-NR effectively resolved the interference in the plasma and enabled accurate alloantibody identification. Although the reduction in evorpacept binding to RBCs was identified via flow cytometry, Evo-NR was incapable of resolving the serologic interference observed in DAT and antigen typing at IAT phase. Discussion: Evorpacept showed constant panreactivity and a carryover effect at high concentrations. Evo-NR successfully resolved the interference in the plasma samples and could be considered a practical and efficient mitigation solution. Implementation of Evo-NR has the potential to support RBC transfusion for patients undergoing evorpacept treatment.

01 Dec 2021·The Lancet. OncologyQ1 · MEDICINE

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Q1 · MEDICINE

Article

Author: Patricia LoRusso ; Hyun Cheol Chung ; Hong I Wan ; Keun-Wook Lee ; Nehal J Lakhani ; Wells A Messersmith ; Pierre Squifflet ; Justin F Gainor ; Yung-Jue Bang ; Jaume Pons ; Frank Stephen Hodi ; Won Seog Kim ; Jeeyun Lee ; Laura Q M Chow ; Sophia S Randolph ; Philip Fanning ; Feng Jin ; Rafael Santana-Davila ; Tracy C Kuo

BACKGROUND:

Both innate and adaptive immune responses are important components of anticancer immunity. The CD47-SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of evorpacept (also known as ALX148), a high-affinity CD47-blocking protein with an inactive IgG Fc region in patients with solid tumours.

METHODS:

We did a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study at nine hospitals and one clinic in the USA and Korea. Eligible patients for the dose-escalation and safety lead-in phases were aged 18 years or older with histological or cytological diagnosis of advanced or metastatic solid tumours with no available standard therapy, measurable or unmeasurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. In the dose-escalation phase, which used a 3 + 3 design, patients received intravenous evorpacept at either 0·3, 1, 3, or 10 mg/kg once per week in 21-day cycles, or 30 mg/kg once every other week in 28-day cycles. In the safety lead-in phase, patients were given the maximum tolerable dose of evorpacept from the dose-escalation phase plus either intravenous pembrolizumab (200 mg administered once every 3 weeks) or intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks). In the dose-expansion phase, additional patients aged 18 years or older with second-line or later-line advanced malignancies were enrolled into three parallel cohorts: those with head and neck squamous cell carcinoma (HNSCC) and those with non-small-cell lung cancer (NSCLC) were given the maximum tolerated dose of evorpacept plus intravenous pembrolizumab (200 mg administered once every 3 weeks), and patients with HER2-positive gastric or gastroesophageal junction cancer were given the maximum tolerated dose of evorpacept plus intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) until disease progression, voluntary withdrawal from the study, or unacceptable toxicity. The primary endpoint was the maximum tolerated dose of evorpacept administered as a single agent and in combination with pembrolizumab or trastuzumab, measured by the occurrence of dose-limiting toxicities during the first cycle, and was assessed in all patients who had received at least one dose of evorpacept. Secondary outcomes included the safety, tolerability, and antitumour activity of evorpacept, alone or in combination with pembrolizumab or trastuzumab. The primary outcome, safety, and tolerability were assessed in all patients who had received at least one dose of evorpacept, and antitumour activity was assessed in those who recieved at least one dose of study treatment and underwent at least one post-baseline tumor assessment. This trial is registered with ClinicalTrials.gov, NCT03013218.

FINDINGS:

Between March 6, 2017, and Feb 21, 2019, 110 patients received single-agent evorpacept (n=28), evorpacept plus pembrolizumab (n=52), or evorpacept plus trastuzumab (n=30), and were included in the safety analysis. Median follow-up was 29·1 months (95% CI not calculable [NC]-NC) in the single-agent cohort, 27·0 months (25·1-28·8) in the evorpacept plus pembrolizumab cohort, and 32·7 months (27·0-32·7) in the evorpacept plus trastuzumab cohort. Two (7%) dose-limiting toxicities in the first cycle were reported in patients who received single-agent evorpacept; neutropenia with an associated infection in one patient with gastroesophageal junction cancer who received 3 mg/kg once per week, and thrombocytopenia with associated bleeding in one patient with pancreatic cancer who received 30 mg/kg once every other week. No maximum tolerated dose was reached; the maximum administered doses were 10 mg/kg once per week or 30 mg/kg once every other week. The 10 mg/kg once per week dose was used in the expansion cohorts in combination with pembrolizumab or trastuzumab. The most common grade 3 or worse treatment-related adverse events were thrombocytopenia with single-agent evorpacept (two [7%] patients) and evorpacept plus pembrolizumab (two [4%]), and thrombocytopenia (two [7%]) and neutropenia (two [7%]) with evorpacept plus trastuzumab. In patients who received single-agent evorpacept, four treatment-related serious adverse events were reported. Five serious treatment-related adverse events related to evorpacept plus pembrolizumab were reported, and one serious adverse event related to evorpacept plus trastuzumab was reported. In response-evaluable patients in the dose-escalation phase (n=15) receiving single-agent evorpacept once per week, four (27%) had a best overall response of stable disease (two received 0·3 mg/kg, one received 3 mg/kg, and one received 10 mg/kg); in the 11 patients who received single-agent evorpacept at the highest dose of 30 mg/kg once every other week, two (18%) had stable disease. In the dose-expansion cohort, overall responses were recorded in four (20·0%; 95% CI 5·7-43·7) of 20 patients with HNSCC who received evorpacept plus pembrolizumab, in one (5·0%; 0·1-24·9) of 20 patients with NSCLC who received evorpacept plus pembrolizumab, and in four (21·1%; 6·1-45·6) of 19 patients with gastric or gastroesophageal junction cancer who received evorpacept plus trastuzumab.

INTERPRETATION:

The safety findings support the use of evorpacept in combination with pembrolizumab or trastuzumab for patients with advanced solid tumours. Preliminary antitumour activity results support future investigation of evorpacept combined with pembrolizumab or trastuzumab in patients with HNSCC, gastric or gastroesophageal junction cancer, and NSCLC.

FUNDING:

ALX Oncology.

News (Medical) associated with Evorpacept

23 Jan 2025

·ir.alxoncology.com

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The updated results from the ASPEN-06 study will be detailed in the following oral presentation: Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)Abstract Number: 332Presenter: Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in JapanPresentation Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PSTSession Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and StomachLocation: Level 2 Ballroom Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting. About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology cdoherty@alxoncology.com (650) 466-7125 Media Contact: Audra Friis, Sam Brown, Inc. audrafriis@sambrown.com (917) 519-9577

ASCOPhase 2ImmunotherapyClinical Result

13 Dec 2024

·endpts.com

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

This year’s San Antonio Breast Cancer Conference yielded major clinical updates on some of the hottest areas of oncology, from VEGF bispecifics that hope to challenge Merck’s Keytruda on efficacy to oral protein degraders that may offer patients more convenience. There were also a handful of early-stage readouts from drugmakers big and small advancing new and improved takes on established mechanisms or sticking it out with approaches that others have left by the wayside. We’ve rounded up data from these presentations here. BeiGene reported early safety data for its CDK4 selective inhibitor on Thursday. CDK4/6 inhibitors work by inhibiting cell cycling, head of solid tumors Mark Lanasa told Endpoints News in an interview. Most of that inhibition is driven by the CDK4 component, while the CDK6 component can add hematologic toxicity, so selective targeting could help minimize side effects, he said. The Phase 1a trial comprises three cohorts testing BeiGene’s BGB-43395 alone and in doublets with fulvestrant and letrozole in people with advanced or metastatic solid tumors, including HR-positive/HER2-negative breast cancer. The most common side effects were gastrointestinal. Blood-related events like neutropenia (4.6%) and anemia (12.3%) were less common and mostly low-grade. Pfizer is also pursuing CDK4 selective inhibition with an asset called atirmociclib. Back in February, the pharma company told investors the drug is a potential successor to its CDK4/6 inhibitor Ibrance, with benefits including more “complete and continuous” target coverage. On Friday, Pfizer presented preliminary data showing atirmociclib plus letrozole attained a 61% confirmed objective response rate in 33 front-line HR-positive/HER2-negative metastatic breast cancer patients in a Phase 1/2a solid tumor study. There were two instances of grade 2 neutropenia and one case of grade 3 neutropenia. ALX Oncology is advancing an approach that drugmakers like Gilead Sciences have given up on due to safety concerns — targeting CD47. The South San Francisco-based biotech has a broad-ranging clinical program for its candidate, evorpacept, which covers non-Hodgkin lymphoma, multiple myeloma and urothelial cancers. On Tuesday, ALX unveiled results from a Phase 1/2b test of evorpacept plus Jazz Pharmaceuticals’ HER2-targeted bispecific antibody Ziihera in solid tumors, including metastatic breast cancer. In 21 patients with HER2-positive disease, the regimen reached a 33.3% confirmed ORR and 3.6 months of median progression-free survival. The response rates (20%) and PFS (1.9 months) were lower in 15 patients with HER2-low disease. Common side effects included fatigue, nausea and diarrhea, but there were no treatment-related deaths or non-infectious lung side effects, the company said.

Clinical ResultPhase 1Phase 2

12 Dec 2024

·www.globenewswire.com

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced that the company will host a virtual event on Tuesday, December 17, at 5:00 AM PST / 8:00 AM EST to discuss the first data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in heavily pretreated patients with metastatic breast cancer. The data were featured today in a spotlight poster presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS). The poster is now available on the ALX Oncology site under Publications. During the virtual company event, Alberto J. Montero, MD, MBA, Clinical Director, Breast Cancer Medical Oncology Program, Diana Hyland Endowed Chair for Breast Cancer, and Professor of Medicine at University Hospitals Seidman Cancer Center, Case Western Reserve University, and the study’s principal investigator, will provide an overview of the data presented at SABCS 2024 and participate in a fireside chat with Alan Sandler, MD, ALX Oncology’s Chief Medical Officer. Jason Lettmann, Chief Executive Officer at ALX Oncology, will provide opening and closing remarks, highlighting progress and upcoming milestones for the company’s evorpacept clinical program. The event will be webcast live and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under News and Events. To participate in the live event, please register using this link: https://edge.media-server.com/mmc/p/8cce2ndq. An archived webcast will be available following the event. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

ImmunotherapyClinical Study

100 Deals associated with Evorpacept

External Link

KEGG	Wiki	ATC	Drug Bank
D12193	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-expressing Gastric Adenocarcinoma	Phase 3	US	Eli Lilly & Co.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	US	ALX Oncology, Inc.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	JP	Eli Lilly & Co.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	JP	ALX Oncology, Inc.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	AU	ALX Oncology, Inc.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	AU	Eli Lilly & Co.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	BE	Eli Lilly & Co.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	BE	ALX Oncology, Inc.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	CZ	ALX Oncology, Inc.	15 Jan 2022
HER2-expressing Gastric Adenocarcinoma	Phase 3	CZ	Eli Lilly & Co.	15 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05002127 (ASPEN-06, Company_Website) Manual	Phase 2/3	HER2-positive gastric cancer \| HER2 positive Gastroesophageal Junction Adenocarcinoma HER2 Positive	127	Evorpacept + trastuzumab + CYRAMZA + paclitaxel	xvkcqqysja(zdaumuhfia) = vhuyaqdcpl iavdsxuasa (nevyjjjdtk ) View more	Positive	31 Jul 2024
NCT05002127 (ASPEN-06, Company_Website) Manual	Phase 2/3		127	Trastuzumab + CYRAMZA + paclitaxel	xvkcqqysja(zdaumuhfia) = ikwqlhpkww iavdsxuasa (nevyjjjdtk ) View more	Positive	31 Jul 2024
NCT05524545 (ASCO2024) Manual	Phase 1	Locally Advanced Urothelial Carcinoma \| Metastatic urothelial carcinoma	20	Evorpacept 20 mg/kgenfortumab vedotin	iqqkshthtf(mtynfsjxqz) = Not observed. akgbzwgmbe (njlshirtbi ) View more	Positive	24 May 2024
NCT05167409 (ASCO2024) Manual	Phase 2	Metastatic Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS)	16	Evorpacept (E) 15 mg/kgcetuximabpembrolizumab	wkhiuetjzv(kdzbzudpqx) = ofkvtobblt fympjflcrf (hkupuwpojo ) View more	Negative	24 May 2024
NCT05025800 (AACR2024) Manual	Phase 1	Non-Hodgkin Lymphoma	20	Evorpacept+rituximab+lenalidomide	tassianzfo(nlviyyauno) = xaketmqydb ihvosdfdhv (cneqmwsbts ) View more	Positive	05 Apr 2024
NCT05002127 (ASPEN-06, NEWS) Manual	Phase 2	Metastatic HER2 positive gastroesophageal junction cancer \| HER2-positive gastric cancer Second line HER2 Positive	54	Evorpacept 30 mg/kg+trastuzumab + CYRAMZA + paclitaxel	aygiwjewmh(wsrfimcill) = rqcvkqvbur mauddcxdij (pdoypgkhjj ) View more	Positive	03 Oct 2023
NCT05002127 (ASPEN-06, NEWS) Manual	Phase 2		54	trastuzumab + CYRAMZA + paclitaxel	aygiwjewmh(wsrfimcill) = mnbiheustq mauddcxdij (pdoypgkhjj ) View more	Positive	03 Oct 2023
NCT04755244 (ASPEN-05, ASH 12022 \| ASH 22022) Manual	Phase 1/2	Acute Myeloid Leukemia	14	Evorpacept+Venetoclax+Azacitidine	dctqvgdapb(bptflnsfkm) = svsiauirsm dlyysaeuht (jhfhceufvc )	Positive	15 Nov 2022
NCT04675294 (ASPEN-03, SITC2022)	Phase 2	Advanced Head and Neck Squamous Cell Carcinoma First line PD-L1-positive (CPS â¥1) \| human papilloma virus (HPV) (p16) status	-	Evorpacept + Pembrolizumab	bbgncejjxk(bbllldlzrc) = iengslesxc bpbfsnftsa (rszivawkpt )	Positive	07 Nov 2022
NCT03013218 (ASPEN-01, SITC2021)	Phase 1	Squamous Cell Carcinoma of Head and Neck \| Gonorrhea HER2-positive	-	Evorpacept 10 mg/kg QW	lrpsrqojbl(ybkibgcrde) = 8 patients experienced TRAEs, where the most common were urticaria, rash, and diarrhea (each n=3, 17%), fatigue and pruritus (each n=2, 11%) ijrczxwdqm (pwwnezfqos )	Positive	10 Nov 2021
NCT03013218 (ASPEN-01, SITC2021)	Phase 1		-	Evorpacept 15 mg/kg QW		Positive	10 Nov 2021
NCT04417517 (ASPEN-02, ASH 12021 \| ASH 22021) Manual	Phase 1/2	Myelodysplastic Syndromes First line	13	azacitidine+evorpacept	wrsgmmzvyp(epafnrnggi) = No DLTs were observed in any cohort. sdbshkfsxe (pthattjxsg ) View more	Positive	05 Nov 2021
NCT04417517 (ASPEN-02, ASH 12021 \| ASH 22021) Manual	Phase 1/2	Myelodysplastic Syndromes First line	13	azacitidine		Positive	05 Nov 2021
NCT03013218 (ASPEN-01, ESMO_GI2021)	Phase 1	HER2 positive Gastrooesophageal junction cancer Second line trastuzumab	18	ALX148 15 mg/kg QW + Trastuzumab + Ramucirumab + Paclitaxel	shvydelnba(leushedpky) = grade 3 decreased lymphocytes cxyjaarsch (vxleyqyajt )	Positive	03 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis